New Data on Zoliflodacin for Gonorrhea in Chlamydia Coinfected Patients Presented at IDWeek 2026

New data presented at IDWeek 2026 in Washington, D.C., on October 24, 2026, indicate that zoliflodacin (Nuzolvence) maintains high rates of microbiologic eradication of urogenital Neisseria gonorrhoeae in patients also co-infected with Chlamydia trachomatis. While zoliflodacin is approved for uncomplicated urogenital gonorrhea, clinicians are advised to continue testing for and managing chlamydia independently using standard recommended regimens, as zoliflodacin is not approved for chlamydial infections.